Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abraxane in metastasized oesophagogastric carcinoma
NCT02273713Phase 2Completed
- Sponsor
- University of Amsterdam
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of nab-paclitaxel in oesophagogastric carcinoma, sponsored by University of Amsterdam. Primary endpoint: Dose Limiting Toxicity at 12 months. Started Oct 2014; status: completed.
02
Drugs
nab-paclitaxel
03
Conditions
oesophagogastric carcinoma
Beyond the preview
Go deeper on NCT02273713.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02273713.